第55届美国妇科肿瘤学会(SGO)年会将于当地时间3月16-18日在美国圣地亚哥召开。正大天晴药业集团1类创新药安罗替尼(小分子多靶点受体酪氨酸激酶抑制剂)、派安普利单抗(PD-1抑制剂)PD-1抑制剂)本次共有5项研究入选,其中1项口头精选壁报(Oral featured poster)、4项壁报展示。
Anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTER-GO-010)
Anlotinib plus penpulimab plus chemo-less therapy in first-line treatment for persistent, recurrent, or metastatic cervical cancer: A single-arm, phase II study (ALTN-AK105-II-06)
The efficacy and safety of combining anlotinib with albumin-bound paclitaxel and cisplatin in patients with recurrent advanced cervical cancer: A prospective single-arm, open-label, phase II trial
A prospective, single-arm, open-label, phase II clinical trial on efficacy and safety of cadonilimab plus anlotinib for recurrent, metastatic or persistent cervical cancer